HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy.

Abstract
Chronic kidney disease (CKD) is highly prevalent worldwide and represents a major cardiovascular risk factor. Dyslipidemia is present in most patients with CKD and further worsens CKD, creating a vicious cycle. The treatment of CKD-related dyslipidemia has been a controversial topic. The use of statins is recommended in all stages of CKD, but it appears to reduce cardiovascular and renal events only in the early CKD stages, up to stage 3. The use of atorvastatin has proven very beneficial; thus, the earliest we start statin treatment, the better for the patient. Atorvastatin and pitavastatin do not need dose adjustments at any level of renal function. Fibrates can be administered in mixed hyperlipidemia, combined with statins in early CKD stages. Omega-3 fatty acids are useful for treating hypertriglyceridemia in CKD. Antibodies against proprotein convertase subtilisin/kexin type 9 hold promise for a better control of dyslipidemia and a greater reduction of cardiovascular risk.
AuthorsVasilios G Athyros, Konstantinos Tziomalos, Asterios Karagiannis
JournalExpert review of cardiovascular therapy (Expert Rev Cardiovasc Ther) Vol. 13 Issue 9 Pg. 1059-66 ( 2015) ISSN: 1744-8344 [Electronic] England
PMID26206619 (Publication Type: Journal Article, Review)
Chemical References
  • Contrast Media
  • Enzyme Inhibitors
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents
Topics
  • Cardiovascular Diseases (drug therapy, etiology, prevention & control)
  • Contrast Media (adverse effects)
  • Disease Progression
  • Dyslipidemias (drug therapy)
  • Enzyme Inhibitors (therapeutic use)
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
  • Hypolipidemic Agents (therapeutic use)
  • Kidney Diseases (chemically induced, drug therapy)
  • Renal Insufficiency, Chronic (complications, drug therapy)
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: